Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease

Patients with renal disease are at high risk for cardiovascular mortality. Determining which interventions best offset this risk remains a health priority.

To quantify the representation of patients with renal disease in randomized controlled trials for interventions proven efficacious for cardiovascular disease.

We searched MEDLINE for trials published from 1985 through 2005 in 11 major medical and subspecialty journals.

Randomized controlled trials for chronic congestive heart failure and acute myocardial infarction of treatments that are currently listed as class I or II recommendations in the current American College of Cardiology/American Heart Association guidelines were included.

Two reviewers independently abstracted data on study and patient characteristics, renal measurements, outcomes, and prognostic features.

A total of 153 trials were reviewed. Patients with renal disease were reported as excluded in 86 (56%) trials. Patients with renal disease were more likely to be excluded from trials that were multicenter; of moderate enrollment size; North American; that tested renin-angiotensin-aldosterone system antagonists and anticoagulants; and that tested chronic congestive heart failure. Only 8 (5%) original articles reported the proportion of enrolled patients with renal disease, and only 15 (10%) reported mean baseline renal function. While 81 (53%) trials performed subgroup analyses of some baseline characteristic in the original article, only 4 (3%) subgroup analyses of treatment stratified by renal disease were performed.

Major cardiovascular disease trials frequently exclude patients with renal disease and do not provide adequate information on the renal function of enrollees or the effect of interventions on patients with renal disease.